AU2001292423A1 - Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid - Google Patents

Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid

Info

Publication number
AU2001292423A1
AU2001292423A1 AU2001292423A AU9242301A AU2001292423A1 AU 2001292423 A1 AU2001292423 A1 AU 2001292423A1 AU 2001292423 A AU2001292423 A AU 2001292423A AU 9242301 A AU9242301 A AU 9242301A AU 2001292423 A1 AU2001292423 A1 AU 2001292423A1
Authority
AU
Australia
Prior art keywords
formulations
reducing
ursodeoxycholic acid
environmental hormones
eliminating toxicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001292423A
Inventor
Kyong-Up Baik
Kyu-Hyuck Jung
Seung-Kook Park
Jae-Duck Yeon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of AU2001292423A1 publication Critical patent/AU2001292423A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to formulations for reducing or eliminating toxicity of environmental hormone containing as detoxifying agent ursodeoxycholic acid, or pharmaceutically acceptable salts or esters thereof.
AU2001292423A 2000-10-04 2001-09-28 Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid Abandoned AU2001292423A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2000-0058127A KR100368936B1 (en) 2000-10-04 2000-10-04 A Medicine Containing Ursodeoxycholic Acid for Prevention and Treatment of Environmental Hormones
KR0058127 2000-10-04
PCT/KR2001/001643 WO2002028396A1 (en) 2000-10-04 2001-09-28 Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid

Publications (1)

Publication Number Publication Date
AU2001292423A1 true AU2001292423A1 (en) 2002-04-15

Family

ID=19691665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001292423A Abandoned AU2001292423A1 (en) 2000-10-04 2001-09-28 Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid

Country Status (9)

Country Link
US (1) US20040029965A1 (en)
EP (1) EP1322315B1 (en)
JP (1) JP3883506B2 (en)
KR (1) KR100368936B1 (en)
CN (1) CN1204892C (en)
AT (1) ATE514426T1 (en)
AU (1) AU2001292423A1 (en)
ES (1) ES2368992T3 (en)
WO (1) WO2002028396A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
KR100368936B1 (en) * 2000-10-04 2003-01-24 주식회사 대웅 A Medicine Containing Ursodeoxycholic Acid for Prevention and Treatment of Environmental Hormones
ATE506955T1 (en) * 2004-10-15 2011-05-15 Seo Hong Yoo COMPOSITIONS FOR REDUCING THE TOXICITY OF CISPLATIN, CARBOPLATIN AND OXALIPLATIN

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245890B (en) * 1991-04-12 1994-10-25 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS FOR ORAL USE GASTRORESANTS CONTAINING BILE ACIDS.
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5521214A (en) * 1995-01-25 1996-05-28 Eli Lilly And Company Methods of inhibiting environmental estrogens
KR100578669B1 (en) * 1997-05-29 2006-12-07 동아제약주식회사 Transparent soft capsule with ursodeoxycholic acid
KR19990009411A (en) * 1997-07-09 1999-02-05 이웅열 Excellent pharmaceutical composition for the treatment of liver disease
RU2224523C2 (en) * 1998-07-24 2004-02-27 Сео Хонг Ю Bile acid-containing aqueous solution and method for its preparing
KR100293764B1 (en) * 1998-08-10 2001-09-17 박명규 Dioxin toxicity detoxifiers based on ginseng
DE19906290A1 (en) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Orally administered medicament for treating colon cancer comprises ursodesoxycholic acid in gastric fluid resistant coating to provide direct topical action at target site
KR100340763B1 (en) * 1999-09-21 2002-06-20 김권 Pharmaceutical composition comprising natural phenol and polyphenol for protecting male reproductive system against endocrine disruptor induced damage
KR20010037134A (en) * 1999-10-14 2001-05-07 김원규 Solution containing ursodeoxycholic acid and process for the prepration thereof
KR100401456B1 (en) * 1999-12-24 2003-10-11 (주) 한국신과학 기술센타 Pharmaceutical composition comprising pectin effective in inhibiting the male reproductive toxicity
KR20010087593A (en) * 2000-03-08 2001-09-21 김권 A pharmaceutical composition having chlorogenic acid as active component for preventing or treating the declining of male reproduction capability
KR100368936B1 (en) * 2000-10-04 2003-01-24 주식회사 대웅 A Medicine Containing Ursodeoxycholic Acid for Prevention and Treatment of Environmental Hormones

Also Published As

Publication number Publication date
CN1468103A (en) 2004-01-14
KR20020026999A (en) 2002-04-13
US20040029965A1 (en) 2004-02-12
JP2004510739A (en) 2004-04-08
EP1322315B1 (en) 2011-06-29
EP1322315A4 (en) 2004-05-26
EP1322315A1 (en) 2003-07-02
ES2368992T3 (en) 2011-11-24
KR100368936B1 (en) 2003-01-24
WO2002028396A1 (en) 2002-04-11
CN1204892C (en) 2005-06-08
JP3883506B2 (en) 2007-02-21
ATE514426T1 (en) 2011-07-15

Similar Documents

Publication Publication Date Title
AU2274201A (en) Compounds and compositions for delivering active agents
HK1054918A1 (en) Compounds and compositions for delivering active agents
AU2002316811A1 (en) Stable formulation of modified glp-1
IL195055A (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
AU2002210993A1 (en) Medicinal compositions for concominant use as anticancer agents
HK1043594A1 (en) N-heterocyclic derivatives as nos inhibitors
CA2366702A1 (en) Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MXPA04004779A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
AU2001279687A1 (en) Skin conditioning compositions containing compounds for mimicking the effect on skin of retinoic acid
IL148288A0 (en) Indolealkanol ester and indolealkylamide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EP1321145A4 (en) Antitumor agents
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
AU2002239348A1 (en) Pyrazolopyridine derivatives
WO2002015959A3 (en) Compounds and compositions for delivering active agents
MY114944A (en) Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use
RS50046B (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDE AND NITAZOXANIDE
AU2002243643A1 (en) Estradiol-16alpha-carboxylic acid esters as locally active estrogens
AU7270798A (en) Antithrombotic agents
WO2002100338A3 (en) Compound and composition for delivering active agents
AU2001292423A1 (en) Formulations for reducing or eliminating toxicity of environmental hormones containing ursodeoxycholic acid
AU7470098A (en) Antithrombotic agents
AU2001260419A1 (en) Use of n,n'-dibenzyl ethylene diamine n,n'-diacetic acid derivatives as anti-pollution agent
AU2003282868A1 (en) Crystalline 17beta-hydroxy-7alpha- (5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma-lactone
EP1321141A4 (en) Parathyroid hormone production inhibitors containing vitamin d3 derivatives
HK1052946A1 (en) Dry compositions containing hydrophobic amino acid